Epidemiology of Infections in Lung Transplant Recipients Treated With Belatacept
In the first year after belatacept initiation, LuTRs commonly developed CMV infections, EBV+ PTLD, and bacterial infections. Multicenter collaborations are needed to better understand infection risks in LuTRs treated with belatacept.
Authors
- Patrick Tam (ORCID: https://orcid.org/0000-0003-4602-1889)
- Julie M. Steinbrink (ORCID: https://orcid.org/0000-0003-0771-3647)
- Arthur W. Baker (ORCID: https://orcid.org/0000-0002-0914-0291)
- Manuela Carugati (ORCID: https://orcid.org/0000-0002-3187-5905)
- Julia A. Messina (ORCID: https://orcid.org/0000-0001-6411-198X)
- Eileen K Maziarz (ORCID: https://orcid.org/0000-0001-7779-9605)
- Jennifer L. Saullo (ORCID: https://orcid.org/0000-0002-7684-431X)
- Brandon Menachem
- Madeleine R. Heldman (ORCID: https://orcid.org/0000-0002-9424-1870)
- Cameron R. Wolfe (ORCID: https://orcid.org/0000-0002-5365-5030)
- Sana Arif
Institutions
- Duke University (US)
Publication Details
- Journal
- Transplant Infectious Disease
- Published
- 2024-11-04
- DOI
- https://doi.org/10.1111/tid.14403
- Citations
- 4
- Primary Topic
- Transplantation: Methods and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 2.29
Funders
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases